IWR-1

GMP
Synonyms: endo-IWR 1; IWR-1-endo
IWR-1 (IWR-1-endo) (GMP) 是 GMP 级别的 IWR-1 (MS-Z78387),而 GMP 级别的小分子可用作细胞疗法中的辅助试剂;IWR-1 (IWR-1-endo) 是一种靶向 Wnt/β-catenin 的 tankyrase 抑制剂 (IC50 = 180 nM),它参与经典 Wnt 信号转导的关键步骤,即 β-catenin 转位至细胞核并随后激活 TCF/LEF 及表达 Wnt/β-catenin 下游靶标,并通过增强 Axin 支架破坏复合物的稳定性来促进 β-catenin 磷酸化,可用于抗肿瘤研究以及骨肉瘤、结直肠癌和牛皮癣等疾病的研究。
产品编号: MS-G39438 CAS No.: 1127442-82-3 分子式: C25H19N3O3 分子量: 409.44
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

IWR-1 (IWR-1-endo) (GMP) 是 GMP 级别的 IWR-1 (MS-Z78387),而 GMP 级别的小分子可用作细胞疗法中的辅助试剂;IWR-1 (IWR-1-endo) 是一种靶向 Wnt/β-catenin 的 tankyrase 抑制剂 (IC50 = 180 nM),它参与经典 Wnt 信号转导的关键步骤,即 β-catenin 转位至细胞核并随后激活 TCF/LEF 及表达 Wnt/β-catenin 下游靶标,并通过增强 Axin 支架破坏复合物的稳定性来促进 β-catenin 磷酸化,可用于抗肿瘤研究以及骨肉瘤、结直肠癌和牛皮癣等疾病的研究。

生物实验数据

生物活性 IWR-1 (IWR-1-endo) (GMP) is the GMP-grade form of IWR-1 (MS-Z78387), and GMP-grade small molecules can be used as ancillary reagents in cell therapy; IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting Wnt/β-catenin (IC50 = 180 nM) that participates in a key step of canonical Wnt signal transduction, namely the translocation of β-catenin to the nucleus followed by activation of TCF/LEF and expression of Wnt/β-catenin downstream targets, and promotes β-catenin phosphorylation by enhancing the stability of the Axin scaffold destruction complex, making it useful for antitumor research and studies on diseases such as osteosarcoma, colorectal cancer, and psoriasis.
IC50 & Target HT29 cells:24.4 μM, SW48 cells:2.5 μM (EC50), SW48 cells:0.25 μM, Wnt:0.2 μM (EC50), HEK293T cells:26 nM
体外研究
(In Vitro)

IWR-1 (GMP) 对骨肉瘤癌干细胞样细胞 (CSC) 具有细胞毒性。
IWR-1 (GMP) 可抑制结直肠癌细胞系的细胞迁移、侵袭和基质金属蛋白酶活性。
IWR-1 (GMP) (2.5-10 μM,48-96 小时) 能够有效降低 MG-63 和 MNNG-HOS 细胞系来源的细胞球以及亲本细胞球中的细胞球活力,且这种降低呈浓度和时间依赖性。
IWR-1 (GMP) (10 μM,96 小时) 可增加 TUNEL 阳性细胞的数量,在 96 小时时与对照组相比分别增加 4.65 倍和 15.83 倍,并促进 caspases 3/7 的活化,在 MG-63 和 MNNG-HOS 细胞球中分别增加 2.15 倍和 1.27 倍。
IWR-1 (GMP) (10 μM,48 小时) 可诱导 MG-63 和 MNNG-HOS 细胞系来源的细胞球细胞周期停滞在 G2/M 期,并增加 S 期细胞占比。
IWR-1 (GMP) (10 μM,48 小时) 可抑制 MG-6t4 和 MNNG-HOS 细胞中第一代 7 天龄球体的次级球体形成率,分别约为 53% 和 55%。
IWR-1 (GMP) (5-50 μM,24-48 小时) 以剂量和时间依赖性方式降低 HCT116 细胞的增殖。
IWR-1 (GMP) (5-50 μM,24-48 小时) 可抑制 TNF-α 刺激的 HCT116 和 HT29 细胞迁移。

Cell Viability Assay

Cell Line: MG-63 and MNNG-HOS spheres and parent cells
Concentration: 2.5, 5, 7.5, 10 μM
Incubation Time: 48 and 96 h
Result: Reduced cell viability when concentration is higher than 5 μM.
Elicited more than 70% reduction of cell viability in spheres derived from the two cell lines at 96 h with 10 μM.
Had minimal effect on parental cells since the Wnt/β-catenin signaling is absent in these cells. Increased the susceptibility of spheres towards Doxorubicin (MS-B38737) when treated in combination with increasing concentrations of Doxorubicin (0.01-100 μM).

Western Blot Analysis

Cell Line: MG-63 and MNNG-HOS spheres and parent cells
Concentration: 10 μM
Incubation Time: 96 h
Result: Led to an upregulation of Bak and a downregulation of Bcl-2 (key proteins involved in mitochondrial-dependent apoptosis), which contributes to a Bak/Bcl-2 ratio >1 that prone the cells to undergo apoptosis.

RT-PCR

Cell Line: MG-63 and MNNG-HOS spheres and parent cells
Concentration: 10 μM
Incubation Time: 96 h
Result: Led to an upregulation of Bak and a downregulation of Bcl-2 (key proteins involved in mitochondrial-dependent apoptosis), which contributes to a Bak/Bcl-2 ratio >1 that prone the cells to undergo apoptosis.
Results in a higher β-catenin nuclear/cytoplasmic ratio in spheres, indicating an increased Wnt/β-catenin pathway activation in osteosarcoma spheres.
Stabilized Axin2 protein levels.
Diminished the protein expression levels of Cyclin D1 in both parental cells and spheres.

Western Blot Analysis

Cell Line: HCT116 cells
Concentration: 5, 10, 20, 50 μM
Incubation Time: 0, 4, 8, 24, 48 h
Result: Increased the levels of the epithelial marker E-cadherin whilst decreased the mesenchymal markers N-cadherin, Vimentin, and Snail dose- and time-dependently.
Inhibited the EMT process in HCT116 cells effectively.
Decreased β-catenin expression and inhibited the EMT-like expressional changes whereby decreasing N-cadherin and Snail and increasing E-cadherin expressions, even in the presence of TNF-α (MS-R26275) (10 ng/mL for 24 h)-induced EMT stimulation.
Decreased the phosphorylation of Akt in a concentration- and time-dependent manner.
Decreased the surviving expression in a concentration- and time-dependent manner, thereby promoting tumor proliferation directly or indirectly through regulating cancer cell homeostasis.
Reduced MMP activities only when surviving was suppressed.
体内研究
(In Vivo)

IWR-1 (GMP) (5 mg/kg,瘤内注射,每天两次,共注射 12 天) 可显著抑制骨肉瘤小鼠模型中的肿瘤生长。
IWR-1 (GMP) (10 mg/kg,皮下注射,第 1、3、5 天) 可改善 Imiquimod (MS-W79117) 诱发的银屑病样小鼠模型中 IL-36γ (2 μg/只小鼠,第 1、3、5 天) 介导的银屑病皮肤病变加重。

Animal Model: Immunocompromised nude mice (6-week old female Swiss nude) were injected sub-cutaneously the pGL4-transfected MNNG-HOS cells (2×106 cells/100 mL PBS)
Dosage: 5 mg/kg
Administration: Intratumorally, each 2 d for 12 d
Result: Resulted in slower tumor growth rate and reduction in tumor size by 73% and 71% in comparison to control and to Doxorubicin-treated (8 mg/kg, i.p., each 4 d for 12 d) groups.
Enhanced the therapeutic efficacy of Doxorubicin shown by a greater reduction of tumor burden at the end of the treatment in opposite to Doxorubicin alone.
Animal Model: Balb/c mice (aged 6-8 weeks) with shaven back and treated with a daily topical dose of IMQ cream
Dosage: 10 mg/kg
Administration: Subcutaneous injection (s.c.) on days 1, 3, 5
Result: Increased epidermal thickening with keratinocyte thickness.
Significantly diminished the effect of IMQ on hyperplasia in the IMQ+IWR-1 group.
Ameliorated the pathological changes in IL-36γ-induced psoriasiform skin lesion.
Reversed IL-36γ-mediated upregulation of inflammatory factors (IL-17 A and IFN-γ) in psoriatic lesions.
Reversed IL-36γ-mediated upregulation of β-catenin and DKK1 expression.

化学信息

分子量 409.44
分子式 C25H19N3O3
CAS No. 1127442-82-3
别名 endo-IWR 1; IWR-1-endo

储存&溶解度

溶解度信息
DMSO: 85.8 mg/mL (209.55 mM), Sonication is recommended.
体内实验配方
10% DMSO+40% PEG300+ 5% Tween 80 + 45% Saline: 4.29 mg/mL (10.48 mM), Suspension.
10% DMSO+90% Saline: < 4.29 mg/mL (10.48 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4.1 mg/mL (10.01 mM), Suspension.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础